908 Devices raises 2026 revenue outlook after 14% Q1 revenue growth
908 Devices reported first quarter 2026 revenue of $13.4 million, up 14% year over year, and raised its full-year 2026 revenue outlook to $67.0 million to $70.0 million. Net loss from continuing operations widened to $12.0 million from $9.8 million, largely due to a noncash $6.4 million charge tied to contingent consideration. The company also completed its acquisition of NIRLAB SA, a Swiss narcotics-detection company, on May 4, 2026, for a headline price of $15 million, partly paid in company shares.
Key points
- Q1 2026 revenue was $13.4 million, up 14% from the prior year period; net loss from continuing operations was $12.0 million, versus $9.8 million a year earlier.
- 2026 revenue guidance was raised to $67.0 million to $70.0 million, representing 19% to 25% growth over 2025 revenue.
- NIRLAB acquisition closed May 4, 2026: $15 million headline price, including $13 million in cash and 293,368 company shares, with up to $8 million more in shares tied to revenue milestones by December 31, 2027.
- Shares issued to NIRLAB sellers and option holders are subject to a 180-day lock-up period, per the filing.
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.